KR20150139569A - 혈관형성의 유도 및 조절을 위한 조성물 및 방법 및 혈관형성 조절 인자를 확인하기 위한 방법 및 분석법 - Google Patents
혈관형성의 유도 및 조절을 위한 조성물 및 방법 및 혈관형성 조절 인자를 확인하기 위한 방법 및 분석법 Download PDFInfo
- Publication number
- KR20150139569A KR20150139569A KR1020157031446A KR20157031446A KR20150139569A KR 20150139569 A KR20150139569 A KR 20150139569A KR 1020157031446 A KR1020157031446 A KR 1020157031446A KR 20157031446 A KR20157031446 A KR 20157031446A KR 20150139569 A KR20150139569 A KR 20150139569A
- Authority
- KR
- South Korea
- Prior art keywords
- human
- extract
- angiogenesis
- placenta
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000006698 induction Effects 0.000 title abstract description 16
- 238000003556 assay Methods 0.000 title description 14
- 239000000587 angiogenesis modulating agent Substances 0.000 title description 2
- 229940076002 angiogenesis modulator Drugs 0.000 title description 2
- 210000002826 placenta Anatomy 0.000 claims abstract description 141
- 239000000284 extract Substances 0.000 claims abstract description 129
- 230000003169 placental effect Effects 0.000 claims abstract description 26
- 230000001939 inductive effect Effects 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 241000282414 Homo sapiens Species 0.000 claims description 159
- 210000004027 cell Anatomy 0.000 claims description 100
- 108090000623 proteins and genes Proteins 0.000 claims description 95
- 102000004169 proteins and genes Human genes 0.000 claims description 65
- 230000002491 angiogenic effect Effects 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 46
- 210000002889 endothelial cell Anatomy 0.000 claims description 44
- 238000001727 in vivo Methods 0.000 claims description 40
- 239000002904 solvent Substances 0.000 claims description 39
- 239000012620 biological material Substances 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 102000004127 Cytokines Human genes 0.000 claims description 29
- 108090000695 Cytokines Proteins 0.000 claims description 29
- 239000003102 growth factor Substances 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 29
- 238000004113 cell culture Methods 0.000 claims description 26
- 239000000287 crude extract Substances 0.000 claims description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 23
- 239000004202 carbamide Substances 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 22
- 102000008217 Pregnancy Proteins Human genes 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 17
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 17
- 238000004458 analytical method Methods 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 210000004204 blood vessel Anatomy 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 13
- 108010035746 Pregnancy Proteins Proteins 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 11
- 210000003462 vein Anatomy 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 9
- 238000007634 remodeling Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- -1 HAND2 Proteins 0.000 claims description 6
- 101710158668 Placental protein Proteins 0.000 claims description 6
- 210000002469 basement membrane Anatomy 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims description 5
- 239000011343 solid material Substances 0.000 claims description 5
- 101001008527 Homo sapiens Laminin subunit alpha-5 Proteins 0.000 claims description 4
- 102100027450 Laminin subunit alpha-5 Human genes 0.000 claims description 4
- 239000000385 dialysis solution Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 claims description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 101000710873 Homo sapiens Collagen alpha-3(IV) chain Proteins 0.000 claims description 3
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 102100035194 Placenta growth factor Human genes 0.000 claims description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 101150054149 ANGPTL4 gene Proteins 0.000 claims description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims description 2
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 claims description 2
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 claims description 2
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 claims description 2
- 102100036364 Cadherin-2 Human genes 0.000 claims description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims description 2
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 claims description 2
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 claims description 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims description 2
- 101000749842 Homo sapiens Leukocyte cell-derived chemotaxin 1 Proteins 0.000 claims description 2
- 101000796134 Homo sapiens Thymidine phosphorylase Proteins 0.000 claims description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims description 2
- 102100040448 Leukocyte cell-derived chemotaxin 1 Human genes 0.000 claims description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- 210000003038 endothelium Anatomy 0.000 claims 1
- 230000006884 regulation of angiogenesis Effects 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 description 37
- 108010082117 matrigel Proteins 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000000338 in vitro Methods 0.000 description 28
- 239000000523 sample Substances 0.000 description 23
- 238000013459 approach Methods 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 230000035784 germination Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 210000005239 tubule Anatomy 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 108091008025 regulatory factors Proteins 0.000 description 8
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 230000012292 cell migration Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- 102000037983 regulatory factors Human genes 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000010874 in vitro model Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 102100034710 Laminin subunit gamma-1 Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229960004198 guanidine Drugs 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001023 pro-angiogenic effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000004088 microvessel Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003990 molecular pathway Effects 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102100040006 Annexin A1 Human genes 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 102100034612 Annexin A4 Human genes 0.000 description 2
- 102100034283 Annexin A5 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 description 2
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 description 2
- 101000924461 Homo sapiens Annexin A4 Proteins 0.000 description 2
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 description 2
- 101000972491 Homo sapiens Laminin subunit alpha-2 Proteins 0.000 description 2
- 101000972488 Homo sapiens Laminin subunit alpha-4 Proteins 0.000 description 2
- 101001008568 Homo sapiens Laminin subunit beta-1 Proteins 0.000 description 2
- 101001008558 Homo sapiens Laminin subunit beta-2 Proteins 0.000 description 2
- 101000946306 Homo sapiens Laminin subunit gamma-1 Proteins 0.000 description 2
- 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
- 102100022743 Laminin subunit alpha-4 Human genes 0.000 description 2
- 102100027448 Laminin subunit beta-1 Human genes 0.000 description 2
- 102100024629 Laminin subunit beta-3 Human genes 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 2
- 108010031099 Mannose Receptor Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100029494 Neutrophil defensin 1 Human genes 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 108010028309 kalinin Proteins 0.000 description 2
- 108010090909 laminin gamma 1 Proteins 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000002407 tissue scaffold Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 description 1
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010012646 Diabetic blindness Diseases 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101001000001 Homo sapiens Basement membrane-specific heparan sulfate proteoglycan core protein Proteins 0.000 description 1
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 description 1
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000049951 Nuclear Factor 45 Human genes 0.000 description 1
- 108700031302 Nuclear Factor 45 Proteins 0.000 description 1
- 102000015863 Nuclear Factor 90 Proteins Human genes 0.000 description 1
- 108010010424 Nuclear Factor 90 Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 101150095658 ilf2 gene Proteins 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 238000005312 nonlinear dynamic Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000037197 vascular physiology Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3808—Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1347—Smooth muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/04—Screening or testing on artificial tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361807401P | 2013-04-02 | 2013-04-02 | |
| US61/807,401 | 2013-04-02 | ||
| PCT/US2014/032696 WO2014165602A1 (en) | 2013-04-02 | 2014-04-02 | Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150139569A true KR20150139569A (ko) | 2015-12-11 |
Family
ID=51621067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157031446A Withdrawn KR20150139569A (ko) | 2013-04-02 | 2014-04-02 | 혈관형성의 유도 및 조절을 위한 조성물 및 방법 및 혈관형성 조절 인자를 확인하기 위한 방법 및 분석법 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9821013B2 (https=) |
| EP (1) | EP2981273B1 (https=) |
| JP (1) | JP2016516091A (https=) |
| KR (1) | KR20150139569A (https=) |
| AU (1) | AU2014248198B2 (https=) |
| CA (1) | CA2908562A1 (https=) |
| HK (1) | HK1221402A1 (https=) |
| WO (1) | WO2014165602A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020036245A1 (ko) * | 2018-08-17 | 2020-02-20 | 고려대학교 산학협력단 | 인간 신경줄기세포의 기능강화 및 생산을 위한 태반유래 세포 조건화 배지 및 이의 용도 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2999420A1 (en) | 2005-09-27 | 2007-04-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| WO2012149486A1 (en) | 2011-04-28 | 2012-11-01 | Tissuetech, Inc. | Methods of modulating bone remodeling |
| EP2717888B1 (en) | 2011-06-10 | 2020-09-09 | Tissuetech, Inc. | Methods of processing fetal support tissues |
| HK1221402A1 (zh) | 2013-04-02 | 2017-06-02 | University Of Florida Research Foundation, Inc. | 用於诱导并调节血管生成的组合物和方法以及用於鉴别血管生成调节剂的方法和实验 |
| TW201603818A (zh) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | 組成物及方法 |
| WO2016138025A2 (en) | 2015-02-23 | 2016-09-01 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
| TWI720984B (zh) | 2015-05-20 | 2021-03-11 | 美商帝聖工業公司 | 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法 |
| US12551509B2 (en) | 2015-11-18 | 2026-02-17 | Lucina Patent Holdco, Llc | Acellular regenerative products and methods of their manufacture |
| TW201733600A (zh) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | 胎兒扶持組織物及使用方法 |
| WO2020081817A1 (en) * | 2018-10-17 | 2020-04-23 | University Of Florida Research Foundation | Magnetically responsive composite microparticles for triggered delivery of biologically active agents |
| CA3135546A1 (en) | 2019-04-04 | 2020-10-08 | THT Biomaterials GmbH | A novel human-material-based platform technology for tissue engineering |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4829000A (en) * | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
| US4994559A (en) | 1985-12-17 | 1991-02-19 | Synergen, Inc. | Human basic fibroblast growth factor |
| JP2770926B2 (ja) * | 1985-12-17 | 1998-07-02 | サイナーゲン インコーポレーテッド | 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子 |
| JPS63152322A (ja) * | 1986-09-30 | 1988-06-24 | Ichimaru Pharcos Co Ltd | プラセンタ−組織由来フイブロネクチン含有溶液 |
| CA2005600A1 (en) | 1988-12-20 | 1990-06-20 | Cal-Henrik Heldin | Endothelial cell growth factor |
| AUPM425294A0 (en) | 1994-03-04 | 1994-03-31 | Australian National University, The | In-vitro angiogenesis assay |
| US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
| JPH0931100A (ja) * | 1995-07-24 | 1997-02-04 | Nippon Ham Kk | 変性コラーゲン及びその製造方法 |
| JP2003501092A (ja) | 1999-06-07 | 2003-01-14 | エドワーズ ライフサイエンシーズ コーポレイション | 標的化新脈管形成 |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| WO2002053191A1 (en) * | 2001-01-05 | 2002-07-11 | Viromed Limited | Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof |
| AU2003220966A1 (en) * | 2002-04-03 | 2003-10-13 | Naohide Yamashita | Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells |
| EP1496878A4 (en) | 2002-04-12 | 2007-12-26 | Celgene Corp | TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS |
| US8940292B2 (en) * | 2003-01-28 | 2015-01-27 | Wake Forest University Health Sciences | Enhancement of angiogenesis to grafts using cells engineered to produce growth factors |
| WO2005003317A2 (en) * | 2003-07-01 | 2005-01-13 | Regents Of The University Of Minnesota | Engineered blood vessels |
| JP2005065661A (ja) * | 2003-08-20 | 2005-03-17 | Akihiro Yamaguchi | ヒト血管内皮細胞のＶＥＧＦ誘導性活性化及び血管新生におけるＩｄの役割 |
| US7775965B2 (en) | 2004-03-09 | 2010-08-17 | The Board Of Regents Of The University Of Oklahoma | Decellularized grafts from umbilical cord vessels and process for preparing and using same |
| US8187639B2 (en) * | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
| CA2999420A1 (en) * | 2005-09-27 | 2007-04-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| US8003388B2 (en) * | 2006-03-24 | 2011-08-23 | Nortis, Inc. | Method for creating perfusable microvessel systems |
| US20080131522A1 (en) | 2006-10-03 | 2008-06-05 | Qing Liu | Use of placental biomaterial for ocular surgery |
| CA2700613C (en) | 2007-09-26 | 2022-09-20 | Celgene Cellular Therapeutics | Angiogenic cells from human placental perfusate |
| US8642333B2 (en) * | 2008-02-04 | 2014-02-04 | Massachusetts Institute Of Technology | Particulate delivery vehicles for embryoid bodies |
| JP2011514169A (ja) * | 2008-03-17 | 2011-05-06 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 幹細胞培養のためのマイクロキャリア |
| US8685634B2 (en) * | 2009-03-06 | 2014-04-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Neural scaffolds |
| CA2769038A1 (en) * | 2009-07-31 | 2011-02-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Antiangiogenic small molecules and methods of use |
| KR101118017B1 (ko) | 2009-09-04 | 2012-02-24 | (주)차바이오앤디오스텍 | 태반 추출물을 제조하는 방법 및 태반 추출물 |
| EP2521861B1 (de) * | 2010-03-30 | 2015-05-27 | Siemens Aktiengesellschaft | Solarthermisches kraftwerk mit indirekter verdampfung und verfahren zum betrieb eines solchen solarthermischen kraftwerks |
| KR20140071813A (ko) | 2012-12-04 | 2014-06-12 | 삼성전자주식회사 | 파이버 상에 형성된 저항성 메모리 소자 및 그 제종 방법 |
| HK1221402A1 (zh) | 2013-04-02 | 2017-06-02 | University Of Florida Research Foundation, Inc. | 用於诱导并调节血管生成的组合物和方法以及用於鉴别血管生成调节剂的方法和实验 |
-
2014
- 2014-04-02 HK HK16109532.8A patent/HK1221402A1/zh unknown
- 2014-04-02 KR KR1020157031446A patent/KR20150139569A/ko not_active Withdrawn
- 2014-04-02 CA CA2908562A patent/CA2908562A1/en not_active Abandoned
- 2014-04-02 AU AU2014248198A patent/AU2014248198B2/en not_active Ceased
- 2014-04-02 WO PCT/US2014/032696 patent/WO2014165602A1/en not_active Ceased
- 2014-04-02 US US14/243,123 patent/US9821013B2/en active Active
- 2014-04-02 EP EP14779851.6A patent/EP2981273B1/en active Active
- 2014-04-02 JP JP2016506585A patent/JP2016516091A/ja active Pending
-
2015
- 2015-05-07 US US15/309,306 patent/US10300091B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020036245A1 (ko) * | 2018-08-17 | 2020-02-20 | 고려대학교 산학협력단 | 인간 신경줄기세포의 기능강화 및 생산을 위한 태반유래 세포 조건화 배지 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016516091A (ja) | 2016-06-02 |
| WO2014165602A1 (en) | 2014-10-09 |
| AU2014248198A1 (en) | 2015-10-29 |
| US20170209497A1 (en) | 2017-07-27 |
| EP2981273A4 (en) | 2016-10-26 |
| US10300091B2 (en) | 2019-05-28 |
| US9821013B2 (en) | 2017-11-21 |
| EP2981273A1 (en) | 2016-02-10 |
| US20140294780A1 (en) | 2014-10-02 |
| HK1221402A1 (zh) | 2017-06-02 |
| EP2981273B1 (en) | 2020-09-16 |
| CA2908562A1 (en) | 2014-10-09 |
| AU2014248198B2 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150139569A (ko) | 혈관형성의 유도 및 조절을 위한 조성물 및 방법 및 혈관형성 조절 인자를 확인하기 위한 방법 및 분석법 | |
| Ratanavaraporn et al. | Synergistic effects of the dual release of stromal cell-derived factor-1 and bone morphogenetic protein-2 from hydrogels on bone regeneration | |
| Moore et al. | Novel human-derived extracellular matrix induces in vitro and in vivo vascularization and inhibits fibrosis | |
| EP2210622B1 (en) | Therapeutic agent for heart disease, which is intended to be used in cell transplantation therapy | |
| Browne et al. | Modulation of inflammation and angiogenesis and changes in ECM GAG-activity via dual delivery of nucleic acids | |
| US20200071676A1 (en) | Three-dimensional culture of primary cancer cells using tumor tissue | |
| KR20110106302A (ko) | 암 치료를 위한 세포외 기질 조성물 | |
| CN103937737A (zh) | 分离的肾细胞及其用途 | |
| JP6855377B2 (ja) | 改変内皮細胞を含む生体適合性インプラント | |
| Zhang et al. | Transplantation of olfactory ensheathing cells combined with chitosan down-regulates the expression of P2X7 receptor in the spinal cord and inhibits neuropathic pain | |
| WO2015015655A1 (ja) | フックス角膜内皮ジストロフィ不死化細胞株およびその作製法 | |
| CN116635091B (zh) | 胸腺构建体及其用途 | |
| Huang et al. | Beneficial Effects of Astragaloside IV‐Treated and 3-Dimensional‐Cultured Endothelial Progenitor Cells on Angiogenesis and Wound Healing | |
| JP7702110B2 (ja) | ヒト膵癌オルガノイドを用いたマウスモデルの樹立 | |
| WO1991001760A1 (en) | Human tumor cells implanted in non-human animals | |
| Tang et al. | Hypoxia‐induced factor 1α promotes osteotomy‐induced regional acceleratory phenomenon via DC‐STAMP mediated membrane fusion | |
| Yang et al. | Reconstituting human cutaneous regeneration in humanized mice under endothelial cell therapy | |
| EP2607478A1 (en) | Phenanthroline treated MSC | |
| CN118160682A (zh) | 一种色素沉着绒毛结节性滑膜炎动物模型的构建方法及应用 | |
| KR101561744B1 (ko) | 3차원 세포이식용 패치 및 그의 제조방법 | |
| Maiborodin et al. | Angiogenesis in rat uterine scar after introduction after autological mesenchymal stem cells of bone marrow origin | |
| CN115948338B (zh) | 一种恶性多形性腺瘤组织块mpa9h-1及其用途 | |
| AU2015255907A1 (en) | Sustained release angiogenesis modulating compositions and methods for induction and modulation of angiogenesis | |
| Gilmore | Repair Schwann cells: bridging the gap for successful nerve repair in the PNS | |
| Jiang | Non-bone marrow CD34+ stem cells are crucial for endothelial repair of injured arteries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151102 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |